Physician profile
Pedro Rivera
NPI 1396367934
$2,813.99
in general payments reported to CMS, 2019-2025
13 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $1,095 · 2024: $1,044 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $772.55 | 2023-2025 | Azure Xt Dr Mri Surescan, Micra, Reacttm |
| Boston Scientific Corporation | $770.36 | 2023-2025 | Emblem Mri S-Icd, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $309.61 | 2023-2025 | Evenity, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $187.34 | 2022-2024 | Farxiga, Lokelma |
| E.R. Squibb & Sons, L.L.C. | $166.92 | 2022-2024 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $134.90 | 2024-2025 | |
| Pbg Puerto Rico LLC | $128.28 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.00 | 2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $94.48 | 2023-2024 | Xarelto, Darzalex |
| Pfizer INC. | $72.68 | 2025 | |
| Merck Sharp & Dohme LLC | $33.50 | 2023-2024 | Verquvo, Gardasil 9, Gardasil |
| Genzyme Corporation | $24.32 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.05 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedro Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.